Bruce K. Crowther net worth and biography

Bruce Crowther Biography and Net Worth

Director of NeoGenomics

Mr. Crowther has served as a Director since October 2014. Mr. Crowther retired in 2013 as President and Chief Executive Officer of Northwest Community Healthcare where he served for 23 years. Northwest Community Healthcare is an award winning hospital offering a complete system of care. Mr. Crowther has a B.S. in Biology and an M.B.A. from Virginia Commonwealth University. Mr. Crowther serves on the Board of Directors of Wintrust Financial Corporation, a public company and serves on the Board of Directors of Barrington Bank and Trust which is a Wintrust Financial Corporation owned Company. He was previously the Chairman and currently a Director of the Max McGraw Wildlife Foundation; a not for profit organization committed to conservation education and research.

What is Bruce K. Crowther's net worth?: The estimated net worth of Bruce K. Crowther is at least $1.02 million as of June 8th, 2021. Mr. Crowther owns 59,564 shares of NeoGenomics stock worth more than $1,021,523 as of December 25th. This net worth estimate does not reflect any other investments that Mr. Crowther may own. Learn More about Bruce K. Crowther's net worth.
How do I contact Bruce K. Crowther?: The corporate mailing address for Mr. Crowther and other NeoGenomics executives is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. NeoGenomics can also be reached via phone at (239) 768-0600 and via email at [email protected]. Learn More on Bruce K. Crowther's contact information.
Has Bruce K. Crowther been buying or selling shares of NeoGenomics?: Bruce K. Crowther has not been actively trading shares of NeoGenomics within the last three months. Most recently, Bruce K. Crowther sold 20,734 shares of the business's stock in a transaction on Tuesday, June 8th. The shares were sold at an average price of $41.46, for a transaction totalling $859,631.64. Following the completion of the sale, the director now directly owns 59,564 shares of the company's stock, valued at $2,469,523.44. Learn More on Bruce K. Crowther's trading history.
Who are NeoGenomics' active insiders?: NeoGenomics' insider roster includes (), Douglas Brown (Insider), George Cardoza (Insider), Bruce Crowther (Director), Mark Mallon (CEO), Kathryn McKenzie (CFO), and Robert Shovlin (Insider). Learn More on NeoGenomics' active insiders.
Are insiders buying or selling shares of NeoGenomics?: During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 7,762 shares worth more than $118,189.52. The most recent insider tranaction occured on November, 15th when General Counsel Alicia C Olivo sold 5,175 shares worth more than $79,488.00. Insiders at NeoGenomics own 1.3% of the company. Learn More about insider trades at NeoGenomics.
Information on this page was last updated on 11/15/2024.

Bruce K. Crowther Insider Trading History at NeoGenomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/8/2021	Sell	20,734	$41.46	$859,631.64	59,564
9/24/2020	Sell	8,333	$35.01	$291,738.33	46,483
9/22/2020	Sell	2,400	$35.68	$85,632.00	46,483
11/2/2015	Buy	6,400	$7.81	$49,984.00

Bruce K. Crowther Buying and Selling Activity at NeoGenomics

NeoGenomics Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Today's Range

Now: $17.15

$16.29

$17.17

50 Day Range

MA: $15.80

$13.05

$18.43

2 Week Range

Now: $17.15

$12.77

$20.94

Volume

469,000 shs

Average Volume

805,794 shs

Market Capitalization

$2.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.